D. McKenna

D. McKenna, T. Eastlund, M. Segall, 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

A multicenter evaluation of heterogeneity in cellular therapy processing laboratory procedure times to assess workload capacity.

Suzanne R. Thibodeaux, J. Reems, M. Fontaine, 2020, Transfusion.

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

C. Le, J. Wagner, Jeffrey S. Miller, 2005, Blood.

Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation.

J. Wagner, Jeffrey S. Miller, B. Blazar, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

haploidentical NK cells in cancer patients Successful adoptive transfer and in vivo expansion of human

Jeffrey S. Miller, D. Weisdorf, A. Panoskaltsis-Mortari, 2012 .

Transfusion‐associated graft‐versus‐host disease: a perspective from a cell therapy laboratory

J. Miller, D. Sumstad, D. McKenna, 2009, Transfusion.

Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

H. Ott, C. Blaisdell, P. Anversa, 2013, American journal of respiratory and critical care medicine.

Combinations of Osmolytes, Including Monosaccharides, Disaccharides, and Sugar Alcohols Act in Concert During Cryopreservation to Improve Mesenchymal Stromal Cell Survival.

A. Hubel, P. Dosa, D. McKenna, 2016, Tissue engineering. Part C, Methods.

Multicenter evaluation of the IL‐3‐pSTAT5 assay to assess the potency of cryopreserved stem cells from cord blood units: The BEST Collaborative study

D. Stroncek, J. Reems, N. Pineault, 2022, Transfusion.

Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study

Doris A Taylor, T. Henry, C. Pepine, 2012, Transfusion.

Umbilical cord blood: Current status & promise for the future

D. McKenna, J. Sheth, 2011, The Indian journal of medical research.

Results of a Phase 1 , Randomized , Double-Blind , Placebo-Controlled Trial of Bone Marrow Mononuclear Stem Cell Administration in Patients Following STEMI

T. Henry, J. Traverse, J. Lesser, 2010 .

Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction.

T. Henry, J. Traverse, J. Lesser, 2010, American heart journal.

Failure of intrathecal allogeneic mesenchymal stem cells to halt progressive demyelination in two boys with cerebral adrenoleukodystrophy

G. Raymond, D. Nascene, D. McKenna, 2020, Stem cells translational medicine.

Postthaw characterization of umbilical cord blood: markers of storage lesion

A. Hubel, D. McKenna, J. Curtsinger, 2015, Transfusion.

Systemic Administration of Human Bone Marrow‐Derived Mesenchymal Stromal Cell Extracellular Vesicles Ameliorates Aspergillus Hyphal Extract‐Induced Allergic Airway Inflammation in Immunocompetent Mice

D. McKenna, S. Kourembanas, S. A. Mitsialis, 2015, Stem cells translational medicine.

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

T. Waldmann, G. Vercellotti, Jeffrey S. Miller, 2017 .

First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings.

J. Wagner, Jeffrey S. Miller, M. MacMillan, 2021, Blood advances.

Regulatory T cells: A review of manufacturing and clinical utility

J. Wagner, T. Mamo, Jeffrey S. Miller, 2022, Transfusion.

University of Minnesota - Molecular and Cellular Therapeutics (MCT)

D. McKenna, 2009 .

Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study.

J. Hare, D. Sumstad, D. Styers, 2022, Cytotherapy.

Autologous stem cell transplant recipients tolerate haploidentical related‐donor natural killer cell–enriched infusions

R. V. van Etten, K. Miller, D. Kadidlo, 2013, Transfusion.

Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity.

J. Cleveland, S. Sebti, J. Pidala, 2020, JCI insight.

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.

Doris A Taylor, B. Byrne, D. Gordon, 2009, American heart journal.

Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative

D. Stroncek, J. Reems, M. Fontaine, 2020, Frontiers in Cell and Developmental Biology.

Therapeutic potential of mesenchymal stem cells for severe acute lung injury.

B. Thompson, M. Matthay, Kathleen D. Liu, 2010, Chest.

Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.

J. Wagner, Jeffrey S. Miller, M. MacMillan, 2009, Blood.

cGMP Production of MSCs

D. McKenna, D. Hei, 2013 .

with umbilical cord blood: safety profile and detection kinetics Infusion of ex vivo expanded T regulatory cells in adults transplanted

J. Wagner, B. Levine, C. June, 2011 .

Umbilical cord blood: current status and future directions

D. McKenna, C. Brunstein, 2011, Vox sanguinis.

The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory.

J. Wagner, Jeffrey S. Miller, D. Kadidlo, 2005, Transfusion medicine reviews.

decitabine vorinostat and haploidentical natural killer cell infusions with il 2 atimulation in high risk myelodysplastic syndrome

M. Patnaik, J. Miller, D. McKenna, 2018 .

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Bin Zhang, Jeffrey S. Miller, D. Weisdorf, 2014, Blood.

Good manufacturing practices production of natural killer cells for immunotherapy: a six‐year single‐institution experience

J. Wagner, Jeffrey S. Miller, D. Weisdorf, 2007, Transfusion.

Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings.

J. Sperry, E. Angelantonio, Jasmine Schwartz, 2019, Anesthesiology.

Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia

D. Prough, D. Herndon, M. Matthay, 2014, Thorax.

Impact of starting material (fresh versus cryopreserved marrow) on mesenchymal stem cell culture

D. Sumstad, D. McKenna, Alesia Kaplan, 2017, Transfusion.

Mesenchymal Stromal Cell Production in Academic Centers: Challenges and Opportunities

D. McKenna, 2017 .

Variations in novel cellular therapy products manufacturing.

D. Stroncek, J. Reems, M. Fontaine, 2020, Cytotherapy.

Mislabeled units of umbilical cord blood detected by a quality assurance program at the transplantation center.

J. Wagner, H. Noreen, D. Kadidlo, 2009, Blood.

Cellular Engineering

D. Stroncek, D. McKenna, 2021, Transfusion Medicine.

Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

J. Wagner, J. Tolar, C. Rooney, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

COVID19 seroconversion in an unrelated stem cell donor

S. Devine, D. Weisdorf, M. Arora, 2020, Bone Marrow Transplantation.

Clinical mesenchymal stromal cell products undergo functional changes in response to freezing.

A. Hubel, D. Sumstad, D. Kadidlo, 2015, Cytotherapy.

Clinical mesenchymal stem cell products experience functional changes in response to freezing

A. Hubel, D. Sumstad, D. Kadidlo, 2014 .

Intra-BM injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLA-matched units

J. Wagner, D. Weisdorf, J. Miller, 2009, Bone Marrow Transplantation.

Healthy versus Inflamed Lung Environments Differentially Effect MSCs

Cláudia Cristina dos Santos, A. Ashare, B. Stanton, 2021 .

Cord blood banking and quality issues

D. McKenna, J. McCullough, Amanda Murphy, 2016, Transfusion.

Adoptive Transfer of Umbilical Cord Blood (UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative Unrelated Double UCB Transplantation.

J. Wagner, B. Levine, C. June, 2009 .

Development of allogeneic iPS cell‐based therapy: from bench to bedside

D. McKenna, Rita C R Perlingeiro, 2022, EMBO Molecular Medicine.

Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control

Jeffrey S. Miller, V. Bachanova, D. McKenna, 2019, Journal of immunotherapy.

Allogeneic Human Mesenchymal Stem Cells Inhibit Bacterial Growth And Restore Normal Alveolar Fluid Transport In An Ex Vivo Perfused Human Lung Injured By Live E. Coli

M. Matthay, Xiaohui Fang, D. McKenna, 2011, ATS 2011.

American Thoracic Society Meeting 2011. Am. J. Respir. Crit. Care Med. 2011;183: A1247: Allogeneic Human Mesenchymal Stem Cells Inhibit Bacterial Growth and Restore Normal Lung Fluid Balance in an Ex Vivo Perfused Human Lung Injured by live E.coli.

M. Matthay, D. McKenna, E. Read, 2011 .

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

J. Wagner, B. Levine, C. June, 2011, Blood.

A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression.

John M Centanni, Peiman Hematti, J. M. Centanni, 2015, Cytotherapy.

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

M. Exline, J. Christman, K. Delucchi, 2019, The Lancet. Respiratory medicine.

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial.

B. Thompson, A. Leavitt, M. Matthay, 2015, The Lancet. Respiratory medicine.

Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome

K. Delucchi, B. Thompson, A. Leavitt, 2014, Annals of Intensive Care.

Cryopreservation of Hematopoietic Stem Cells: Emerging Assays, Cryoprotectant Agents, and Technology to Improve Outcomes

A. Hubel, D. McKenna, Guanglin Yu, 2019, Transfusion Medicine and Hemotherapy.

Preservation of cell-based immunotherapies for clinical trials.

A. Hubel, D. McKenna, Guanglin Yu, 2019, Cytotherapy.

Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices

Allison Hubel, Kathryn Pollock, David McKenna, 2014, Transfusion.

Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples

D. Kadidlo, D. McKenna, J. McCullough, 2005, Transfusion.

Algorithm‐driven optimization of cryopreservation protocols for transfusion model cell types including Jurkat cells and mesenchymal stem cells

A. Hubel, P. Dosa, D. McKenna, 2017, Journal of tissue engineering and regenerative medicine.

Evaluation of post‐thaw CFU‐GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant

J. Wagner, D. Sumstad, D. McKenna, 2019, Transfusion.

Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative.

John McMannis, David McKenna, Hermann Eichler, 2013, Cytotherapy.

Viability does not necessarily reflect the hematopoietic progenitor cell potency of a cord blood unit: results of an interlaboratory exercise

J. Reems, J. Hess, H. Eichler, 2008, Transfusion.

Massive ex Vivo Expansion of Human Natural Regulatory T Cells (Tregs) with Minimal Loss of in Vivo Functional Activity

Bruce R. Blazar, Daniel C. Douek, Bruce L. Levine, 2011, Science Translational Medicine.

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

L. Downs, K. Dusenbery, P. Judson, 2011, Cytotherapy.

Issues in the quality of umbilical cord blood stem cells for transplantation

J. Wagner, D. Kadidlo, D. McKenna, 2005, Transfusion.

High-Grade Gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2012, Oxford Medicine Online.

Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs

Simon C Watkins, D. Stolz, N. Kaminski, 2015, Nature Communications.

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade

Natalie K. Wolf, Walker S. Lahr, Beau R. Webber, 2020, bioRxiv.

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Jeffrey S. Miller, V. Bachanova, Z. Cayci, 2019, Blood.

Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria.

M. Matthay, Yuanlin Song, D. McKenna, 2013, American journal of respiratory and critical care medicine.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Doris A Taylor, B. Byrne, D. Gordon, 2010, Texas Heart Institute journal.

Improved Post-Thaw Function and Epigenetic Changes in Mesenchymal Stromal Cells Cryopreserved Using Multicomponent Osmolyte Solutions.

A. V. van Wijnen, A. Dudakovic, A. Hubel, 2017, Stem cells and development.

Translational Research in Acute Lung Injury and Pulmonary Fibrosis Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation

J. Laffey, M. Matthay, D. McAuley, 2014 .

Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T‐cell subpopulations

J. Reems, J. Cancelas, D. McKenna, 2017, Transfusion.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

C. Le, J. Wagner, B. Levine, 2016, Blood.

Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.

Jakub Tolar, Todd E DeFor, Claudio G Brunstein, 2016, Cell stem cell.

J. Wagner, K. Weinberg, D. McKenna, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Storage characteristics of cord blood progenitor cells: report of a multicenter study by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative

J. Reems, D. McKenna, J. Mcmannis, 2011, Transfusion.

Consistency of the initial cell acquisition procedure is critical to the standardization of CD34+ cell enumeration by flow cytometry: results of a pairwise analysis of umbilical cord blood units and cryopreserved aliquots

J. Wagner, R. Bornstein, D. McKenna, 2009, Transfusion.

In reply

D. McKenna, J. Mcmannis, Z. Szczepiorkowski, 2011 .

Impact of long-term cryopreservation on single umbilical cord blood transplantation outcomes.

J. Wagner, M. Verneris, D. McKenna, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Graft-Recipient ABO Compatibility on Outcomes after Umbilical Cord Blood Transplant for Nonmalignant Disease.

D. McKenna, R. Shanley, Angela R. Smith, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors Predicting Single-Unit Predominance after Double Umbilical Cord Blood Transplantation

J. Wagner, Jeffrey S. Miller, D. Weisdorf, 2011, Bone Marrow Transplantation.

Interlaboratory assessment of a novel colony‐forming unit assay: a multicenter study by the cellular team of Biomedical Excellence for Safer Transfusion (BEST) collaborative

J. Reems, E. Grassman, D. Sumstad, 2011, Transfusion.

Cell motion and recovery in a two-stream microfluidic device

E. Longmire, A. Hubel, D. McKenna, 2010, Microfluidics and nanofluidics.

Experimental study of diffusion-based extraction from a cell suspension

E. Longmire, A. Hubel, D. McKenna, 2008 .

Complement fragment 3a priming of umbilical cord blood progenitors: safety profile.

J. Wagner, M. Ratajczak, D. Weisdorf, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Current practices for viability testing of cryopreserved cord blood products: an international survey by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative

D. Stroncek, J. Reems, M. Fontaine, 2018, Transfusion.

Loss of integrity of umbilical cord blood unit freezing bags: description and consequences

D. Sumstad, D. McKenna, B. Thyagarajan, 2008, Transfusion.

Comparative analysis of cell therapy infusion workflows at clinical sites.

J. Ritz, S. Nikiforow, A. Hubel, 2021, Cytotherapy.

Impact of Delayed Infusion Time in Umbilical Cord Blood Transplantation.

M. Verneris, D. McKenna, R. Mitchell, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Microbial contamination of hematopoietic stem cell products: incidence and clinical sequelae.

D. Kadidlo, D. McKenna, J. McCullough, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy To Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed by a Double UCBT in Patients with Refractory AML.

C. Le, K. Dusenbery, Jeffrey S. Miller, 2006 .

Multicenter study on in vitro characterization of dendritic cells.

D. Roelen, H. Eichler, D. McKenna, 2008, Cytotherapy.

Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response

A. Dietz, W. Low, C. Moertel, 2014, Journal of Immunotherapy for Cancer.

How do i participate in T‐cell immunotherapy?

D. McKenna, P. Norris, Megan M Suhoski Davis, 2017, Transfusion.

TRF_14832 854..857

D. Stroncek, D. McKenna, A. Mathew, 2019 .

Developments in clinical cell therapy.

S. Heimfeld, M. Sabatino, C. Rooney, 2010, Cytotherapy.

Controlled, Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells 2 to 3 Weeks after Acute Myocardial Infarction

Doris A Taylor, B. Byrne, T. Henry, 2010 .

Postthaw filtration of umbilical cord blood does not affect product quality or likelihood of engraftment

D. Kadidlo, D. McKenna, Bruce R. Lindgren, 2011, Transfusion.

Healthy versus inflamed lung environments differentially affect mesenchymal stromal cells

M. Matthay, C. D. dos Santos, A. Ashare, 2021, European Respiratory Journal.

Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells

Cláudia Cristina dos Santos, D. Matthews, M. Wargo, 2020, American journal of physiology. Lung cellular and molecular physiology.

Lung inflammatory environments differentially alter mesenchymal stromal cell behavior

M. Wargo, R. Loi, M. Matthay, 2019, American journal of physiology. Lung cellular and molecular physiology.

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

N. Geller, N. Munshi, M. Pasquini, 2021, Blood.

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Jeffrey S. Miller, V. Bachanova, Z. Cayci, 2020, Blood.

Keli L . Hippen with Minimal Loss of in Vivo Functional Activity ) regsMassive ex Vivo Expansion of Human Natural Regulatory T Cells ( T

J. Wagner, D. Douek, B. Levine, 2011 .

Intravenous Allogeneic Human Mesenchymal Stem Cells Home To The Site Of Injury And Restore Alveolar Fluid Clearance To A Normal Level In An Ex Vivo Perfused Human Lung Injured By E.Coli Endotoxin

M. Matthay, Xiaohui Fang, Yuanlin Song, 2010, ATS 2010.

CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine.

A. Donnenberg, R. Lindblad, A. Gee, 2010, Cytotherapy.

Challenges in the cGMP manufacturing of MSCs for multicenter academia trials

D. McKenna, 2016, Transfusion.

Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome - authors' reply.

M. Matthay, D. McKenna, Kathleen D. Liu, 2015, The Lancet. Respiratory medicine.

Differentiation of umbilical cord blood-derived multilineage progenitor cells into respiratory epithelial cells.

D. McKenna, D. Collins, M. Berger, 2006, Cytotherapy.

Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML

T. Waldmann, Jeffrey S. Miller, D. Weisdorf, 2012 .

Hemolytic anemia due to passenger lymphocyte syndrome in solid malignancy patients treated with allogeneic natural killer cell products

D. McKenna, R. Skeate, S. Cooley, 2013, Transfusion.

Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia

K. Dusenbery, Jeffrey S. Miller, D. Weisdorf, 2011 .

Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma

Justin H Hwang, Cheng-Ying Wu, N. Snyder, 2023, Science Translational Medicine.

StemRegenin-1 (SR1) Expansion Culture Abrogates the Engraftment Barrier Associated with Umbilical Cord Blood Transplantation (UCBT)

Anthony E. Boitano, J. Wagner, M. Cooke, 2014 .

Harvest Quality, Nucleated Cell Dose and Clinical Outcomes in Bone Marrow Transplantation: A Retrospective Study.

M. MacMillan, D. Sumstad, D. McKenna, 2022, Transplantation and Cellular Therapy.

Physicochemical Mechanisms of Protection Offered by Agarose Encapsulation during Cryopreservation of Mammalian Cells in the Absence of Membrane-Penetrating Cryoprotectants.

A. Aksan, D. McKenna, Mian Wang, 2023, ACS applied bio materials.

Traveling treatment: medical tourism in the emerging era of potentially transmissible therapeutics

T. Gniadek, D. McKenna, C. Cohn, 2017, Transfusion.

High grade gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2022, Progress in Brain Research.

First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Jeffrey S. Miller, D. Weisdorf, V. Bachanova, 2019, Biology of Blood and Marrow Transplantation.

Acceleration of Umbilical Cord Blood (UCB) Stem Engraftment: Results of a Phase I Clinical Trial with Stemregenin-1 (SR1) Expansion Culture

Anthony E. Boitano, J. Wagner, M. Cooke, 2015 .

Safety and Exploratory Efficacy Of Ex Vivo Expanded Umbilical Cord Blood (UCB) Hematopoietic Stem and Progenitor Cells (HSPC) Using Cytokines and Stem-Regenin 1 (SR1): Interim Results Of a Phase 1/2 Dose Escalation Clinical Study

Anthony E. Boitano, M. Cooke, C. Bleul, 2013 .

Improved Post-Thaw Function and Epigenetic Changes in Mesenchymal Stromal Cells Cryopreserved Using Multicomponent Osmolyte Solutions.

A. V. van Wijnen, A. Dudakovic, A. Hubel, 2017, Stem cells and development.

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Bin Zhang, Jeffrey S. Miller, D. Weisdorf, 2014, Blood.

Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells

Jeffrey S. Miller, D. Weisdorf, B. Blazar, 2008 .

Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

H. Ott, C. Blaisdell, P. Anversa, 2013, American journal of respiratory and critical care medicine.

Doris A Taylor, B. Byrne, D. Gordon, 2009, American heart journal.

Assessment of stored red blood cells through lab-on-a-chip technologies for precision transfusion medicine

Umut A. Gurkan, O. B. Usta, M. Toner, 2023, Proceedings of the National Academy of Sciences of the United States of America.

A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells

T. Waldmann, Jeffrey S. Miller, D. Weisdorf, 2015 .

Autologous stem cell transplant recipients tolerate haploidentical related‐donor natural killer cell–enriched infusions

R. V. van Etten, K. Miller, D. Kadidlo, 2013, Transfusion.

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Anthony E. Boitano, M. Cooke, John C. Davis, 2019, Blood.